
Afatinib 40 mg (Afanat) is a targeted anticancer medicine used to treat certain types of non-small cell lung cancer (NSCLC) with specific EGFR mutations. It helps slow the growth and spread of cancer cells by blocking proteins that promote tumour growth. Afatinib is usually prescribed after confirming the presence of EGFR mutations through appropriate testing.
| Generic name | Afatinib |
| Strength | 40 mg |
| Manufacturer | Natco |
| Package size | 28 Tablets |
| Used for | Non-small cell lung cancer (NSCLC) |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Afatinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It works by blocking EGFR proteins that send signals for cancer cell growth and division. This helps stop the multiplication of cancer cells and slows the spread of the disease.
Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.